Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–99.

Article  CAS  Google Scholar 

Giacomelli R, Afeltra A, Alunno A, Baldini C, Bartoloni-Bocci E, Berardicurti O, et al. International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren’s syndrome)?: the unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev. 2017;16(9):911–24.

Article  Google Scholar 

Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American college of rheumatology/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366–83.

Article  CAS  Google Scholar 

Almutairi K, Nossent J, Preen DB, Keen H, Inderjeeth C. The temporal association between hospital admissions, biological therapy usage and direct health care costs in rheumatoid arthritis patients. Rheumatol Int. 2021;42(11):2027–37.

Article  Google Scholar 

Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious complications of biological and small molecule targeted immunomodulatory therapies. Clin Microbiol Rev. 2020;33(3):e00035.

Article  CAS  Google Scholar 

Minozzi S, Bonovas S, Lytras T, Pecoraro V, Gonzalez-Lorenzo M, Bastiampillai AJ, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15(sup1):11–34.

Article  CAS  Google Scholar 

Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1101–36.

Article  Google Scholar 

Rathmann J, Jayne D, Segelmark M, Jonsson G, Mohammad AJ. Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study. Rheumatology (Oxford). 2021;60(6):2745–54.

Article  Google Scholar 

Banerjee S, Biehl A, Ghaderi-Yeganeh M, Manna Z, Hasni S. Low incidence of opportunistic infections in lupus patients treated with cyclophosphamide and steroids in a tertiary care setting. Med Res Arch. 2017. https://doi.org/10.18103/mra.v5i3.1084.

Article  Google Scholar 

Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010;69(2):380–6.

Article  CAS  Google Scholar 

Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011;70(4):616–23.

Article  CAS  Google Scholar 

Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(10):2675–84.

Article  CAS  Google Scholar 

Sakai R, Tanaka E, Nishina H, Suzuki M, Yamanaka H, Harigai M. Risk of opportunistic infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis, using a Japanese health insurance database. Int J Rheum Dis. 2019;22(11):1978–84.

Article  CAS  Google Scholar 

Lindstrom U, Exarchou S, Lie E, Dehlin M, Forsblad-d’Elia H, Askling J, et al. Childhood hospitalisation with infections and later development of ankylosing spondylitis: a national case-control study. Arthritis Res Ther. 2016;18(1):240.

Article  Google Scholar 

Tektonidou MG, Wang Z, Dasgupta A, Ward MM. Burden of serious infections in adults with systemic lupus erythematosus: a national population-based study, 1996–2011. Arthritis Care Res (Hoboken). 2015;67(8):1078–85.

Article  Google Scholar 

Tieu J, Lester S, Raymond W, Keen HI, Hill CL, Nossent J. Mortality and cause of death in patients with AAV/PAN in Australia-a population-based study. Rheumatology (Oxford). 2021;61(3):1062.

Article  Google Scholar 

Almutairi K, Inderjeeth C, Preen DB, Keen H, Rogers K, Nossent J. The accuracy of administrative health data for identifying patients with rheumatoid arthritis: a retrospective validation study using medical records in Western Australia. Rheumatol Int. 2021;41(4):741–50.

Article  Google Scholar 

Ognjenovic M, Raymond WD, Inderjeeth CA, Keen HI, Preen DB, Nossent JC. The risk and consequences of vertebral fracture in patients with ankylosing spondylitis: a population-based data linkage study. J Rheumatol. 2020;47(11):1629–36.

Article  Google Scholar 

Martin DO, Austin H. Exact estimates for a rate ratio. Epidemiology. 1996;7(1):29–33.

Article  CAS  Google Scholar 

Bright A, Denholm J, Coulter C, Waring J, Stapledon R. On behalf of the national tuberculosis advisory committee, for the communicable diseases network Australia and the Australian mycobacterium reference laboratory network. Tuberculosis notifications in Australia, 2015–2018. Commun. Dis. Intell. 2020;44:39.

Google Scholar 

Nossent J, Inderjeeth C, Keen H, Preen D, Li I, Kelty E. The association between TNF inhibitor therapy availability and hospital admission rates for patients with ankylosing spondylitis a longitudinal population-based study. Rheumatol Ther. 2022;9(1):127–37.

Article  Google Scholar 

Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol. 2020;16(2):207–28.

Article  CAS  Google Scholar 

Leon L, Peñuelas M, Candel FJ, Freites D, Rodriguez-Rodriguez L, Fernandez-Gutierrez B, et al. Indicator opportunistic infections after biological treatment in rheumatoid arthritis, 10 years follow-up in a real-world setting. Ther Adv Musculoskelet Dis. 2019;11:1759720X19878004.

Article  Google Scholar 

Kourbeti IS, Ziakas PD, Mylonakis E. Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis. 2014;58(12):1649–57.

Article  Google Scholar 

Kim H, Cho S-K, Lee J, Bae S-C, Sung Y-K. Increased risk of opportunistic infection in early rheumatoid arthritis. Int J Rheum Dis. 2019;22(7):1239–46.

Article  CAS  Google Scholar 

Hsu CY, Ko CH, Wang JL, Hsu TC, Lin CY. Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study. Arthritis Res Ther. 2019;21(1):211.

Article  Google Scholar 

Sundbaum JK, Arkema EV, Bruchfeld J, Jonsson J, Askling J, Baecklund E. Tuberculosis in biologic-naïve patients with rheumatoid arthritis: risk factors and tuberculosis characteristics. J Rheumatol. 2021;48(8):1243–50.

Article  Google Scholar 

Arkema EV, Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Askling J. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? Ann Rheum Dis. 2015;74(6):1212–7.

Article  CAS  Google Scholar 

Tam LS, Leung CC, Ying SK, Lee GK, Yim CW, Leung YY, et al. Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong–the role of TNF blockers in an area of high tuberculosis burden. Clin Exp Rheumatol. 2010;28(5):679–85.

Google Scholar 

Vuorela M, Mars NJ, Salonen J, Kauppi MJ. Tuberculosis in people with rheumatic disease in Finland 1995–2007: a nationwide retrospective register study. Rheumatol Adv Pract. 2019. https://doi.org/10.1093/rap/rkz020.

Article  Google Scholar 

Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. 2018;77(5):644–9.

Article  CAS  Google Scholar 

Liao TL, Chen YM, Chen DY. Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications. Clin Microbiol Infect. 2016;22(9):815.e1-.e3.

Article  Google Scholar 

Chakravarty EF. Incidence and prevention of herpes zoster reactivation in patients with autoimmune diseases. Rheumatic Dis Clin North Am. 2017;43(1):111–21.

Article  Google Scholar 

Qian J, Lassere MN, Heywood AE, Liu B. Use of disease-modifying antirheumatic drugs and the subsequent risk of herpes zoster in older adults. Rheumatology. 2021;60(11):5042.

Article  CAS  Google Scholar 

Wang S, He Q, Shuai Z. Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Clin Rheumatol. 2018;37(2):439–50.

Article  Google Scholar 

Siegel SAR, Winthrop KL. In the real world: infections associated with biologic and small molecule therapies in psoriatic arthritis and psoriasis. Curr Rheumatol Rep. 2019;21(7):36.

Article  Google Scholar 

Blauvelt A, Ramharter M, Cohen AD, Xu W, Patel H, Schuster C, et al. An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis treated with ixekizumab from 16 clinical studies. J Eur Acad Dermatol Venereol. 2021;35(11):e828–31.

Article  CAS  Google Scholar 

Elewski BE, Baddley JW, Deodhar AA, Magrey M, Rich PA, Soriano ER, et al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. JAMA Dermatol. 2021;157(1):43–51.

Article  Google Scholar 

Baumrin E, Van Voorhees A, Garg A, Feldman SR, Merola JF. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: from the medical board of the national psoriasis foundation. J Am Acad Dermatol. 2019;81(1):102–10.

Article  Google Scholar 

Zou A, Chen Y, Shi N, Ye Y. Risk of herpes zoster associated with biological therapies for psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Medicine (Baltimore). 2021;100(40):e27368.

Article  CAS  Google Scholar 

Serac G, Tubach F, Mariette X, Salmon-Ceron D, Ravaud P, Liote F, et al. Risk of herpes zoster in patients receiving anti-TNF-alpha in the prospective French RATIO registry. J Invest Dermatol. 2012;132(3 Pt 1):726–9.

Article  CAS  Google Scholar 

García-Doval I, Hernández MV, Vanaclocha F, Sellas A, de la Cueva P, Montero D. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts. Br J Dermatol. 2017;176(3):643–9.

Article  Google Scholar 

Roberts-Thomson PJ, Roberts-Thomson RA, Nikoloutsopoulos T, Gillis D. Immune dysfunction in Australian aborigines. Asian Pac J Allergy Immunol. 2005;23(4):235–44.

CAS  Google Scholar